Skip to main content
SpringerLink
Log in

Drug Effects on Dreaming

  • Chapter
Sleep and Sleep Disorders

  • 2108 Accesses

Abstract

Among the proposed functions of dreaming in human being, the most research supports are mood-regulation, problem-solving, learning, and memory construction. Recent imaging techniques have provided meaningful information on functional neuroanatomy and neurophysiology of REM sleep and dreaming. In addition to serotonin, norepinephrine, and acetylcholine in terms of a reciprocal interaction between the cholinergic REM-ON and aminergic REM-OFF neurons suggested by McCarley and Hobson, dopamine has recently began to think to play a significant role in modulation of dream functions, particularly nightmares. The disinhibition of REM physiology is due primarily to dopaminergic dysfunction, specifically the removal of dopaminergic inhibition on amygdalar sites in dopamine-related syndromes including parkinson disease, REM sleep behavior disorder, and narcolepsy. The disinhibited amygdala yields the affective and personality changes, and the unpleasant dreams associated with PD, RBD, and narcolepsy as well as depression. There is limited data in the literature on drugs and dreaming or dream content even if it is well-known that many antidepressant drugs may cause nightmares or frightening dreams. In this chapter, we review and discuss the effects of medications on dreaming.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Maquet P, Franck G. REM sleep and the amygdala. MOlecular Psychiatry 1997; 2:195–196.

    Article  CAS  PubMed  Google Scholar 

  2. Braun AR, Balkin TJ, Wesenten NJ et al. Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)0 PET study. Brain 1997; 120:1173–1197.

    Article  PubMed  Google Scholar 

  3. Nofzinger EA, Mintun MA, Wiseman MB et al. Forebrain activation in REM sleep: An FDG PET study. Brain Research 1997; 770:192–201.

    Article  CAS  PubMed  Google Scholar 

  4. Maquet P. Functional neuroimaging of normal human sleep by positron emission tomography. J Sleep Res 2000; 9:207–231.

    Article  CAS  PubMed  Google Scholar 

  5. Solms M. Dreaming and REM sleep are controlled by different brain mechanisms. Behav Brain Sci 2000; 23:843–850.

    Article  CAS  PubMed  Google Scholar 

  6. McNamara P, Durso R, Auerbach S. Dopaminergic syndromes of sleep, mood and mentation: Evidence from Parkinson’s disease and related disorders. Sleep and Hypnosis 2002; 4:119–131.

    Google Scholar 

  7. Wisor JP, Nishino S, Sora I et al. Dopaminergic role in stimulant-induced wakefulness. Journal of Neuroscience 2001; 21:1787–1794.

    CAS  PubMed  Google Scholar 

  8. Agid Y, Javoy-Agid M, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In: Marsden CD, Fahn S, eds. Movement Disorders. New York: Buttersworth & Co., 1987:166–230

    Google Scholar 

  9. Cipolli C, Bolzani R, Massetani R et al. Dream structure in Parkinson’s patients. Journal of Nervous Mental Disorders 1992; 180:516–523.

    Article  CAS  Google Scholar 

  10. Fosse R, Stickgold R, Hobson JA. Emotional experience during rapid-eye-movement sleep in narcolepsy. Sleep 2002; 25:724–732.

    PubMed  Google Scholar 

  11. Gottesmann C. The neurochemistry of waking and sleeping mental activity: The disinhibition-dopamine hypothesis. Psychiatry and Clinical Neurosciences 2002; 56:345–354.

    Article  CAS  PubMed  Google Scholar 

  12. Portas CM, Bjorvatn B, Ursin R. Serotonin and the sleep/wake cycle: Special emphasis on microdialysis studies. Prog Neurobiol 2000; 60:13–35.

    Article  CAS  PubMed  Google Scholar 

  13. Jones BE. Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience 1991; 40:637–656.

    Article  CAS  PubMed  Google Scholar 

  14. McCarley RW, Massaquoi G. Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control. Journal of Sleep Research 1992; 1:132–137.

    Article  PubMed  Google Scholar 

  15. Monti JM, Jantos H, Monti D et al. Dorsal raphe nucleus administration of 5-HT1A receptor agonist and antagonists: Effect on rapid eye movement sleep in the rat. Sleep Research Online 2000; 3:29–34.

    CAS  PubMed  Google Scholar 

  16. Sorensen E, Gronli J, Bjorvatn B et al. Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Research 2001; 897:122–130.

    Article  CAS  PubMed  Google Scholar 

  17. Sharpley AL, Gregory CA, Solomon RA et al. Slow wave sleep and 5-HT2 receptor sensitivity during maintenance tricyclic antidepressant treatment. Journal of Affective Disorders 2000; 19:273–277.

    Article  Google Scholar 

  18. Sommerfelt L, Ursin R. The 5-HT2 antagonist ritanserin decreases sleep in cats. Sleep 1993; 16:15–22.

    CAS  PubMed  Google Scholar 

  19. Coenen AM, Ates N, Skarsfeldt T et al. Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns, and epileptic activity of rats. Pharmacol Biochem Behav 1995; 51:353–357.

    Article  CAS  PubMed  Google Scholar 

  20. Pace-Schott EF, Gersh T, Silvestri R et al. SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 2001; 10:129–142.

    Article  CAS  PubMed  Google Scholar 

  21. Hobson JA, McCarley RW, Wyzinski PW. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups; Science 1975; 189:55–58.

    Article  CAS  PubMed  Google Scholar 

  22. Siegel JM. Brainstem mechanisms generating REM sleep. GABA release in the dorsal raphe nucleus. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: WB Saunders, 2000:724–741.

    Google Scholar 

  23. Kirschner N. Changes in dream content after drug treatment. Dreaming 1999; 9:195–200.

    Article  Google Scholar 

  24. Ulivelli M, Rossi S, Lombardi C et al. Polysomnographic characterization of pergolide induced sleep attacks in idiopathic PD. Neurology 2002; 58:462–465.

    CAS  PubMed  Google Scholar 

  25. Hartmann E, Russ D, Oldfield M et al. Dream content: Effects of L-Dopa. Sleep Research 1980; 9:153.

    Google Scholar 

  26. Rechtschaffen A, Maron L. The effect of amphetamine on the sleep cycle. Electroencephalogr Clin Neurophysiol 1964; 16:438–445.

    Article  CAS  PubMed  Google Scholar 

  27. Watson R, Hartmann E, Schildkraut JJ. Amphetamine withdrawal: Affective state sleep patterns and MHPG excretion. Am J Psychiatry 1972; 129:39–45.

    Google Scholar 

  28. Reimann D, Hohagen F, Fritsch-Montero R et al. Cholinergic and noradrenergic neurotransmission: Impact on REM sleep regulation in healthy subjects and depressed patients. Acta Psychiatrica Belgica 1992; 92:151–171.

    Google Scholar 

  29. Danguir J, De Saint-Hilaire-Kafi S. Scopolamine-induced suppression of paradoxical sleep is reversed by the somatostatin analogue SMS 201–995 in rats. Pharmacol Biochem Behav 1988; 30:295–297.

    Article  CAS  PubMed  Google Scholar 

  30. Hernandez-Peon R, Chavez-Ibarra G, Morgane PJ et al. Limbic cholinergic pathways involved in sleep and emotional behavior. Exp Neurol 1963; 8:93–111.

    Article  Google Scholar 

  31. Callaway CW, Lydic R, Baghdoyan HA et al. Pontogeniculooccipital waves: Spontaneous visual system activity during rapid eye movement sleep. Cell Mol Neurobiol 1987; 7:105–149.

    Article  CAS  PubMed  Google Scholar 

  32. Gillin JC, Sutton L, Ruiz C et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991; 30:157–169.

    Article  CAS  PubMed  Google Scholar 

  33. Velazquez-Moctezuma J, Gillin JC, Shiromani PJ. Effects of specific M1, M2 muscarinic receptor agonists on REM sleep generation. Brain Res 1989; 503:128–131.

    Article  CAS  PubMed  Google Scholar 

  34. Sitaram N, Moore AM, Gillin JC. The effect of physostigmine on normal human sleep and dreaming. Arch Gen Psychiatry Oct 1978; 35(10):1239–43

    CAS  Google Scholar 

  35. Muzio JN, Roffwarg HP, Kaufman E. Alterations in the nocturnal sleep cycle resulting from LSD. Electroencephalogr Clin Neurophysiol 1966; 21:313–324.

    Article  CAS  PubMed  Google Scholar 

  36. Shiromani P, Gillin JC, Henriksen SJ. Acetylcholine and the regulation of REM sleep: Basic mechanisms and clinical implications for affective illness and narcolepsy. Annu Rev Pharmacol Toxicol 1987; 27:137–156.

    Article  CAS  PubMed  Google Scholar 

  37. Hartmann E. The nightmare: The psychology and biology of terrifying dreams. NY: Basic Books Inc., 1984.

    Google Scholar 

  38. Pavel S, Goldstein R, Petrescu M et al. REM sleep induction in prepubertal boys by vasotocin: Evidence for the involvement of serotonin containing neurons. Peptides 1981; 2:245–50.

    Article  CAS  PubMed  Google Scholar 

  39. Siegel JM, Rogawski MA. A function for REM sleep: Regulation of noradrenergic receptor sensitivity. Brain Res Rev 1988; 13:213–233.

    Article  CAS  Google Scholar 

  40. Depoorte H. Adrenergic agonists and antagonists and sleep-wakefulness stages. In: Wauquier A, Gaillard JM, Monti JM et al, eds. Sleep: Neurotransmitters and Neuromodulators. New York: Raven Press, 1985:79–92.

    Google Scholar 

  41. Coulter JD, Lester BK. Reserpine and sleep. Psychopharmacology 1971; 19:134–147.

    Article  CAS  Google Scholar 

  42. Mignot E, Guilleminault C, Bowersox S et al. Role of central a-1 adrenoceptors in canine narcolepsy. J Clin Invest 1988; 82:885–894.

    Article  CAS  PubMed  Google Scholar 

  43. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep 1989; 12:254–256.

    CAS  PubMed  Google Scholar 

  44. Hilakivi I, Leppavouri A. Effects of methoxamine, an a-1 adrenoceptor agonist, and prazosin, an a-1 antagonist, on the stages of the sleep-wake cycle in the rat. Acta Physiol Scand 1984; 120:363–372.

    Article  CAS  PubMed  Google Scholar 

  45. Nicholson AN, Pascoe PA. Presynaptic a-2 adrenoceptor function and sleep in man: Studies with clonidine and idazoxan. Neuropharmacology 1991; 30:367–372.

    Article  CAS  PubMed  Google Scholar 

  46. Oswald I, Adam K, Allen S et al. A-Adrenergic blocker thymoxamine and mesoridazine both increase human REM sleep duration. Sleep Research 1974; 3:62.

    Google Scholar 

  47. Hilakivi I. The role of b-and a-adrenoreceptors in the regulation of the stages of the sleep-waking cycle in the cat. Brain Res 1983; 227:109–118.

    Article  Google Scholar 

  48. Roth T, Kramer M, Salis PJ. Drugs, REM sleep, and dreams. In: Wolfman BB, ed. Handbook of Dreams. NY: Van Nostrand Reinhold Co., 1979:203–225.

    Google Scholar 

  49. Schredl M, Schafer G, Weber B et al. Dreaming and insomnia: Dream recall and dream content of patients with insomnia. J Sleep Res 1998; 7:191–198.

    Article  CAS  PubMed  Google Scholar 

  50. Riemann D, Low H, Schredl M et al. Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine. Psychiatric Journal of the University of Ottawa 1990; 15:93–99.

    CAS  PubMed  Google Scholar 

  51. Armitage R, Rochlen A, Fitch T et al. Dream recall and major depression: A preliminary report. Dreaming 1995; 5:189–198.

    Google Scholar 

  52. Kirschner N. Changes in dream content after drug treatment. Dreaming 1999; 9:195–200.

    Article  Google Scholar 

  53. Hall CS, Van de Castle R. The Content Analysis of Dreams. NY: Appleton-Century-Crofts, 1966.

    Google Scholar 

  54. Koponen H, Lepola U, Leinonen E et al. Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatr Scand 1997; 96:343–346.

    Article  CAS  PubMed  Google Scholar 

  55. Becker RE, Dufresne RL. Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 1982; 139:1200–1201.

    CAS  PubMed  Google Scholar 

  56. Strayhorn JM, Nash JL. Frightening dreams and dosage schedule of tricyclic and neuroleptic drugs. J Nerv Ment Dis 1978; 166:878–880.

    Article  CAS  PubMed  Google Scholar 

  57. Lepkifker E, Dannon PN, Iancu I et al. Nightmares related to fluxetine treatment. Clin Neuropharmacol 1995; 18:90–94.

    Article  CAS  PubMed  Google Scholar 

  58. Schenck CH, Mahowald MW, Kim SW et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 1992; 15:226–235.

    CAS  PubMed  Google Scholar 

  59. Thompson DF, Pierce DR. Drug-induced nightmares. Ann Pharmacother 1999; 33:93–98.

    Article  CAS  PubMed  Google Scholar 

  60. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34:128–131.

    Article  CAS  PubMed  Google Scholar 

  61. Gillin JC, Smith-Vaniz A, Schnierow B et al. An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. J Clin Psychiatry 2001; 62:789–796.

    CAS  PubMed  Google Scholar 

  62. Lewis JD. Mirtazapine for PTSD Nightmares. Am J Psychiatry 2002; 159:1948–1949.

    Article  PubMed  Google Scholar 

  63. Hartmann E. The nightmare is the most useful dream. Sleep and Hypnosis 1999; 1:199–203.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neuroscience Research Unit, Yuzuncu Yil University School of Medicine, Van, Turkey

    Mehmet Yucel Agargun & Hanefi Ozbek

Authors
  1. Mehmet Yucel Agargun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanefi Ozbek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Landes Bioscience/Eurekah.com and Springer Science+Business Media

About this chapter

Cite this chapter

Agargun, M.Y., Ozbek, H. (2006). Drug Effects on Dreaming. In: Sleep and Sleep Disorders. Springer, Boston, MA. https://doi.org/10.1007/0-387-27682-3_29

Download citation

Publish with us

Policies and ethics

Search

Navigation